Quetmolimab: A Deep Dive into KANAb 001 and E-6011 The agent, quetmolimab, shows a new immunotherapy targeting the PD-1 receptor. Initial clinical findings from both studies, KANAb 001 and E-6011, reveal significant https://www.targetmol.com/compound/quetmolimab